664 results about "Neutralising antibody" patented technology

The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.

The invention discloses a fusion protein of a novel coronavirus envelope protein and an application of the fusion protein. The fusion protein (SARS2-RBD-Fc) is obtained by fusing an RBD structural domain of a novel coronavirus envelope protein S with an antibody Fc fragment; and as a subunit vaccine, the fusion protein can induce an organism to generate an efficient neutralizing antibody through nasal drip immunization and intramuscular injection. It indicates that the SARS2-RBD-Fc can be used as a candidate vaccine for preventing and treating new coronavirus infection.

The present application relates novel HIV-1 broadly neutralizing antibodies. The antibodies of the present invention are further characterized by their ability to bind epitopes from the Env proteins. The invention also provides light and heavy chain variable region sequences. Compositions for prophylaxis, diagnosis and treatment of HIV infection are provided.

The invention discloses a subunit coronavirus vaccine for dimerization-based receptor binding domains and belongs to the technical field of medicine. A baculovirus expresses RBD (receptor binding domain (E367-Y606) of MERS-CoV (middle east respiratory syndrome coronavirus) protein and RBD (R294-F515) of SARS-CoV (severe acute respiratory syndrome coronavirus) in insect cells, the RBDs may form a dimer through cysteine residue at 603 of S (spike) protein or form a dimer through cysteine residue at 512 of the S protein, and purified RBD protein dimer and monomer are used respectively to immunize Bald/c mice. The dimerized RBDs have the advantages that the defect that RBD monomers have poor immunogenicity is overcome and the generation of neutralizing antibodies in against MERS-CoV is increased greatly.

The present invention provides anti-PCI antibodies having Protein C inhibitor (PCI)-neutralizing activity, and the uses thereof. Through the generation and screening of anti-PCI antibodies, the inventors successfully isolated anti-PCI antibodies which inhibit PCI's inhibitory effect on the production and activity of activated Protein C (aPC). The antibodies of the present invention suppress PCI's inhibitory effect on aPC production and/or the aPC inactivation by PCI, and thus can be used to maintain aPC activity and sustain the effects of aPC physiological activities, such as suppression of the activation of blood coagulation system and anti-inflammatory functions. The present invention also provides uses of the antibodies of the present invention in treating diseases such as thrombosis and sepsis using aPC. In treatments by aPC administration, the therapeutic effect of aPC can be sustained by administering an antibody of the present invention. The antibodies of the present invention can be used in the treatment and prevention of diseases such as thrombosis and sepsis.

A novel anti-IL13 receptor α1 antibody having an activity of inhibiting a cell response by IL13, in particular, having an activity of inhibiting the cell response by IL13 but not inhibiting the cell response by IL4, a characteristic amino acid sequence in a variable region thereof, and a method of detecting IL13 receptor α1 in a sample using the same are provided.

The invention concerns a pharmaceutical composition comprising, as the active ingredient, human natural antibodies of the IgG isotype, that neutralize the activity of a human cytokine selected from VEGF, IFNα, IL-4, TNFα and TGFβ, the said neutralizing antibodies inhibiting at least 50% of the maximum biological activity induced by an amount ranging from 0.006 ng to 0.05 ng of the said cytokine in vitro.

The invention relates to an SARS-CoV-2 neutralizing antibody detection kit. The SARS-CoV-2 neutralizing antibody detection kit comprises a solid phase carrier, a first antigen and a second antigen ofS protein of SARS-CoV-2, and the second antigen is marked with a signal substance. Whether a tested person is infected by the new coronavirus or not and whether infection risks exist or not are judgedby detecting a neutralizing antibody through an immunodiagnosis technology, and the method is reliable in theory, practical and feasible and can be completed only in a secondary biosafety laboratory.

The invention relates to a hybridoma cell strain ZJEB8-01, an Ebola-virus GP albumen resistant monoclonal antibody, and preparation and application of the Ebola-virus GP albumen resistant monoclonal antibody. The hybridoma cell strain ZJEB8-01 can be used for secreting the Ebola-virus GP albumen resistant monoclonal antibody. Binding of the monoclonal antibody and the 412th-431st amino acid sequence antigen peptides of Ebola-virus GP albumen has high specificity and sensitiveness, and the monoclonal antibody can be applied to preparation of Ebola-virus GP albumen detection reagents. Sequencing of the monoclonal antibody is completed, and the material basis is laid for humanization transformation of monoclonal antibody sequences, research and development of the neutralizing antibody for neutralizing Ebola viruses and development of the antibody into clinical Ebola virus treatment antibody in later period.

This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses.

The invention discloses a colloidal gold immunochromatographic test strip for detecting a neutralizing antibody secreted in vivo after injection of a novel coronavirus vaccine and a preparation methodof the colloidal gold immunochromatographic test strip. The test strip comprises a PVC bottom plate, and a sample pad, a colloidal gold pad, a nitrocellulose membrane and water absorption filter paper are sequentially lapped on the PVC bottom plate from left to right; the colloidal gold pad is coated with a recombinant novel coronavirus RBD protein marked by colloidal gold; and the nitrocellulosemembrane is coated with an angiotensin converting enzyme 2 (ACE2) detection line and coated with a mouse anti-chicken IgG antibody as a quality control line. According to the colloidal gold immunochromatography test strip, a competitive method is adopted to detect the neutralizing antibody in a human body, the sensitivity, specificity, repeatability and stability are high, the recovery rate of atarget compound is high, and the detection result is accurate and reliable. The test strip realizes rapid qualitative detection of the neutralizing antibody in a human body after injection of a novelcoronavirus vaccine, has high sensitivity and small intra-batch and inter-batch difference, and provides great convenience for clinical use.

The present invention provides methods and compositions to induce neutralizing antibodies in mammals to serotypes of dengue virus, measles virus, mumps virus, rubella and/or VZV virus.